Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883775 · ClinicalTrials.gov registry record · Phase 1
Study of a New Technique for Imaging Pancreatic Cancer
A Phase 1 study of Pancreatic Cancer and Tumors That Express CA19-9, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 7
- Study locations
NCT04883775: Completed Phase 1 study of Pancreatic Cancer and Tumors That Express CA19-9, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04883775 is a Phase 1 study of Pancreatic Cancer and Tumors That Express CA19-9 that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04883775, a Phase 1 study of Pancreatic Cancer and Tumors That Express CA19-9, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.
Primary Outcome
assessed by CTCAE v4.0
Conditions Studied
Interventions
- DRUG MVT-2163
- DRUG MVT-5873
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Consent Only) - Commack
- Memorial Sloan Kettering Westchester (Consent only) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent Only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent only) - Middletown
- Memorial Sloan Kettering Bergen (Consent only ) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 1 |
What the finished NCT04883775 record still lists
NCT04883775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which MVT-2163 is the first listed.
NCT04883775 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04883775 about?
NCT04883775 is a clinical study titled "Study of a New Technique for Imaging Pancreatic Cancer". The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.
What is the current status of trial NCT04883775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-05-10. Estimated completion is 2025-01-27.
What conditions does trial NCT04883775 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Tumors That Express CA19-9.
What interventions are being tested in trial NCT04883775?
The interventions under investigation include: MVT-2163 (DRUG), MVT-5873 (DRUG).
Who is sponsoring clinical trial NCT04883775?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04883775 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04883775's enrollment target sits among peer trials
4 276th of 278 higher than 2 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI